Lyell used the preoperative serum albumin level as a biomarker to predict survival prognosis and the occurrence of any postoperative complications in patients receiving pelvic exenteration surgery in colorectal, genitourinary, and gynecologic cancer [33]. This evidence concerns the gene ALB and female reproductive organ cancer.